New Hampshire Trust Buys 544 Shares of Medtronic PLC $MDT

New Hampshire Trust increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 8.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,996 shares of the medical technology company’s stock after acquiring an additional 544 shares during the period. New Hampshire Trust’s holdings in Medtronic were worth $610,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MDT. Brighton Jones LLC boosted its stake in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares in the last quarter. GAMMA Investing LLC boosted its stake in Medtronic by 41.1% during the first quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock worth $1,427,000 after acquiring an additional 4,626 shares in the last quarter. Golden State Wealth Management LLC boosted its stake in Medtronic by 180.8% during the first quarter. Golden State Wealth Management LLC now owns 2,752 shares of the medical technology company’s stock worth $247,000 after acquiring an additional 1,772 shares in the last quarter. Perigon Wealth Management LLC boosted its stake in Medtronic by 7.5% during the first quarter. Perigon Wealth Management LLC now owns 13,735 shares of the medical technology company’s stock worth $1,234,000 after acquiring an additional 953 shares in the last quarter. Finally, Western Wealth Management LLC boosted its stake in Medtronic by 14.9% during the first quarter. Western Wealth Management LLC now owns 5,628 shares of the medical technology company’s stock worth $506,000 after acquiring an additional 730 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on MDT shares. Wells Fargo & Company boosted their price objective on shares of Medtronic from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 20th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a report on Saturday. BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. William Blair raised shares of Medtronic to a “hold” rating in a report on Friday, July 11th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $107.00 target price (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.82.

Insider Activity at Medtronic

In other Medtronic news, Director William R. Jellison bought 2,500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares of the company’s stock, valued at $461,850. This represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

Shares of NYSE MDT opened at $93.76 on Friday. The firm has a 50 day moving average of $94.32 and a 200 day moving average of $89.39. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $120.26 billion, a price-to-earnings ratio of 25.83, a price-to-earnings-growth ratio of 2.47 and a beta of 0.78. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $99.37.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date was Friday, September 26th. Medtronic’s payout ratio is 78.24%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.